(R)-3-((2S,3S)-3-((S)-2-((S)-2-amino-2-phenylacetamido)-3,3-dimethylbutanamido)-2-hydroxy-4-phenylbutanoyl)-5,5-dimethyl-N-neopentylthiazolidine-4-carboxamide

ID: ALA447735

Chembl Id: CHEMBL447735

PubChem CID: 44560420

Max Phase: Preclinical

Molecular Formula: C35H51N5O5S

Molecular Weight: 653.89

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Synonyms: KNI-10680 | CHEMBL447735|KNI-10680|BDBM50478922

Canonical SMILES:  CC(C)(C)CNC(=O)[C@H]1N(C(=O)[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](N)c2ccccc2)C(C)(C)C)CSC1(C)C

Standard InChI:  InChI=1S/C35H51N5O5S/c1-33(2,3)20-37-31(44)28-35(7,8)46-21-40(28)32(45)26(41)24(19-22-15-11-9-12-16-22)38-30(43)27(34(4,5)6)39-29(42)25(36)23-17-13-10-14-18-23/h9-18,24-28,41H,19-21,36H2,1-8H3,(H,37,44)(H,38,43)(H,39,42)/t24-,25-,26-,27+,28+/m0/s1

Standard InChI Key:  PITLJSCJQDTWGC-APNLASKRSA-N

Associated Targets(non-human)

prt Protease (104 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
protease Protease (2551 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 653.89Molecular Weight (Monoisotopic): 653.3611AlogP: 3.15#Rotatable Bonds: 11
Polar Surface Area: 153.86Molecular Species: NEUTRALHBA: 7HBD: 5
#RO5 Violations: 1HBA (Lipinski): 10HBD (Lipinski): 6#RO5 Violations (Lipinski): 2
CX Acidic pKa: 12.04CX Basic pKa: 7.23CX LogP: 3.29CX LogD: 3.07
Aromatic Rings: 2Heavy Atoms: 46QED Weighted: 0.25Np Likeness Score: 0.45

References

1. Zhang M, Nguyen JT, Kumada HO, Kimura T, Cheng M, Hayashi Y, Kiso Y..  (2008)  Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme.,  16  (14): [PMID:18558491] [10.1016/j.bmc.2008.05.052]
2. Nguyen JT, Kato K, Kumada HO, Hidaka K, Kimura T, Kiso Y..  (2011)  Maintaining potent HTLV-I protease inhibition without the P3-cap moiety in small tetrapeptidic inhibitors.,  21  (6): [PMID:21316958] [10.1016/j.bmcl.2011.01.048]
3. Nguyen JT, Kato K, Hidaka K, Kumada HO, Kimura T, Kiso Y..  (2011)  Design and synthesis of several small-size HTLV-I protease inhibitors with different hydrophilicity profiles.,  21  (8): [PMID:21392990] [10.1016/j.bmcl.2011.02.066]

Source